Bausch Health Companies Inc.: Psoriasis trials

The registry lists 24 Psoriasis studies with Bausch Health Companies Inc. as lead sponsor. 1 are open to participants now and 16 have results posted.

Phase 1 5Phase 2 8Phase 3 6Phase 4 3No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling by invitationNCT03254667
• Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisCompletedNCT03837743Phase 2Results posted
• Safety and Efficacy of IDP-122 Lotion When Applied Topically to Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02785185Phase 2Results posted
• Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque PsoriasisCompletedNCT02785172Phase 2Results posted
• Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedNCT02785159Phase 2Results posted
• Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque PsoriasisCompletedNCT02514577Phase 3Results posted
• Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque PsoriasisCompletedNCT02462083Phase 3Results posted
• Safety and Efficacy of IDP-118 in the Treatment of Plaque PsoriasisCompletedNCT02462070Phase 3Results posted
• A Bioequivalence Study Comparing a Single 1.5mL Dose of Brodalumab vs. Two Doses (1.0mL + 0.5mL) of BrodalumabCompletedNCT02173392Phase 1Results posted
• Safety and Efficacy of IDP 118 in the Treatment of Plaque PsoriasisCompletedNCT02045277Phase 2Results posted
• Brodalumab Drug-Drug Interaction (DDI) and Intensive Pharmacodynamic (PK) Study in Psoriasis SubjectsCompletedNCT01937260Phase 1Results posted
• Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis SubjectsTerminatedNCT01708629Phase 3Results posted
• P3 Study Brodalumab in Treatment of Moderate to Severe Plaque PsoriasisTerminatedNCT01708603Phase 3Results posted
• Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab in Moderate to Severe Plaque Psoriasis SubjectsTerminatedNCT01708590Phase 3Results posted
• Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With PsoriasisTerminatedNCT01101100Phase 2Results posted
• Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With PsoriasisCompletedNCT00975637Phase 2Results posted
• Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827CompletedNCT00867100Phase 1Results posted
• Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work ProductivityActive, not recruitingNCT05132231
• A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent RegimenCompletedNCT04149587
• A Safety and Pharmacokinetics Study of IDP-118 Lotion in Pediatric Participants With Plaque PsoriasisCompletedNCT03988439Phase 4
• A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque PsoriasisActive, not recruitingNCT03987763Phase 4
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric SubjectsActive, not recruitingNCT03240809Phase 4
• Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03058744Phase 1
• A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118Status unknownNCT01670513Phase 1/2